- Home
- EKSO vs TOVX Comparison
EKSO vs TOVX Comparison
Compare EKSO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EKSO | TOVX |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | EKSO | TOVX |
|---|---|---|
| Price | $5.56 | $0.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | 326.9K | ★ 3.0M |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,749,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $54.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.73 | $0.17 |
| 52 Week High | $14.97 | $2.03 |
Technical Indicators
Market Signals| Indicator | EKSO | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 46.07 |
| Support Level | $4.56 | $0.18 |
| Resistance Level | $5.09 | $0.23 |
| Average True Range (ATR) | 0.30 | 0.02 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 92.68 | 60.31 |
Price Performance
Historical ComparisonAbout EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.